• Login
  • Register
The Daily Sceptic
No Result
View All Result
  • Articles
  • About
  • Archive
    • ARCHIVE
    • NEWS ROUND-UPS
  • Podcasts
  • Newsletter
  • Premium
  • Donate
  • Log In
The Daily Sceptic
No Result
View All Result

Ivermectin: Cheap Covid Treatment Shown to be Highly Effective in New Peer-Reviewed Study

by Will Jones
3 May 2021 10:38 PM

A new peer-reviewed study by Dr Pierre Kory and colleagues on Ivermectin has been published in the American Journal of Therapeutics. Entitled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19“, it provides a new authoritative overview of the evidence to date and calls for the widely available drug to be “globally and systematically deployed in the prevention and treatment of COVID-19”.

The study summarises the impressive evidence base for the use of Ivermectin.

1. Since 2012, multiple in vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue, and others.
2. Ivermectin inhibits SARS-CoV-2 replication and binding to host tissue through several observed and proposed mechanisms.
3. Ivermectin has potent anti-inflammatory properties with in vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-κB (NF-κB), the most potent mediator of inflammation.
4. Ivermectin significantly diminishes viral load and protects against organ damage in multiple animal models when infected with SARS-CoV-2 or similar coronaviruses.
5. Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients.
6. Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms.
7. Ivermectin hastens recovery and avoidance of ICU admission and death in hospitalised patients.
8. Ivermectin reduces mortality in critically ill patients with COVID-19.
9. Ivermectin leads to temporally associated reductions in case fatality rates in regions after ivermectin distribution campaigns.
10. The safety, availability, and cost of ivermectin are nearly unparalleled given its low incidence of important drug interactions along with only mild and rare side effects observed in almost 40 years of use and billions of doses administered.
11. The World Health Organisation has long included ivermectin on its “List of Essential Medicines.”

The quality of the evidence for Ivermectin has been challenged, leading many countries including the U.K. and U.S. not to recommend its use for COVID-19. The study takes this criticism head-on.

Although a subset of trials are of an observational design, it must be recognised that in the case of ivermectin (1) half of the trials used a randomised controlled trial design (12 of the 24 reviewed above) and (2) observational and randomised trial designs reach equivalent conclusions on average as reported in a large Cochrane review of the topic from 2014. In particular, OCTs that use propensity-matching techniques (as in the Rajter study from Florida) find near identical conclusions to later-conducted RCTs in many different disease states, including coronary syndromes, critical illness, and surgery. Similarly, as evidenced in the prophylaxis and treatment trial meta-analyses as well as the summary trials table, the entirety of the benefits found in both OCT and RCT trial designs aligns in both direction and magnitude of benefit. Such a consistency of benefit among numerous trials of varying sizes designs from multiple different countries and centres around the world is unique and provides strong, additional support.

A hint of the politics around Ivermectin can be gleaned in the discussion section, where the authors wonder how much more evidence a cheap, safe drug like Ivermectin needs in an international emergency before it can be approved.

The continued challenges faced by health care providers in deciding on appropriate therapeutic interventions in patients with COVID-19 would be greatly eased if more updated and commensurate evidence-based guidance came from the leading governmental health care agencies. Currently, in the United States, the treatment guidelines for COVID-19 are issued by the National Institutes of Health. Their most recent recommendation on the use of ivermectin in patients with COVID-19 was last updated on February 11th, 2021, where they found that “there was insufficient evidence to recommend for or against ivermectin in COVID-19”. For a more definitive recommendation to be issued by major leading public health agencies (PHA), it is apparent that even more data on both the quality and quantity of trials are needed, even during a global health care emergency, and in consideration of a safe, oral, low-cost, widely available and deployable intervention such as ivermectin.

The authors add that further evidence is on its way and express an earnest hope that “if the above benefits in clinical outcomes continue to be reported in the remaining trials … this almost doubling of the current supportive evidence base would merit a recommendation for use by the WHO, NIH, and other PHAs”.

The study includes two striking graphs, from Peru and Uruguay, illustrating the strong association of Ivermectin use with reduction in Covid infections and deaths.

Alto Parana used Ivermectin from where the line goes bold whereas the other states did not
In Peru, Lima did not use Ivermectin whereas the other states did

Considering how quickly vaccines using novel technology with unproven long-term safety records have been authorised for use, the failure to approve a known safe drug with considerable evidence to suggest clinical benefit is almost inexplicable. Some have suggested the resistance has been motivated by a wish among pharmaceutical companies to prioritise more profitable medicines like the vaccines. If so, this is a criminal example of putting profits before people.

It is good to see this study make it to publication. (There are rumours that some journals rejected it, not for any technical reason but because it would be controversial, possibly with their sponsors.) It is to be hoped there will be many more such studies, and a sea-change in regulators’ attitudes to repurposed medicines like Ivermectin.

Tags: IvermectinTreatments

Donate

We depend on your donations to keep this site going. Please give what you can.

Donate Today

Comment on this Article

You’ll need to set up an account to comment if you don’t already have one. We ask for a minimum donation of £5 if you'd like to make a comment or post in our Forums.

Sign Up
Previous Post

Britain Records One Covid Death in Lowest Daily Toll in Nine Months – Yet Boris Doggedly Sticks to Roadmap

Next Post

News Round Up

Subscribe
Login
Notify of
Please log in to comment

To join in with the discussion please make a donation to The Daily Sceptic.

Profanity and abuse will be removed and may lead to a permanent ban.

93 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments

NEWSLETTER

View today’s newsletter

To receive our latest news in the form of a daily email, enter your details here:

DONATE

PODCAST

Episode 36 of the Sceptic: Karl Williams on Starmer’s Phoney Immigration Crackdown, Dan Hitchens on the Assisted Suicide Bill and Tom Jones on Reform’s Local Council Challenge

by Richard Eldred
16 May 2025
0

LISTED ARTICLES

  • Most Read
  • Most Commented
  • Editor’s Picks

Chinese ‘Kill Switches’ Found in US Solar Farms

15 May 2025
by Will Jones

News Round-Up

16 May 2025
by Richard Eldred

Spy Agency Report on the Alleged “Extremism” of AfD Turns Out to Be So Stupid That it Destroys all Momentum for Banning the Party

16 May 2025
by Eugyppius

Renaud Camus on the Destruction of Western Education

15 May 2025
by Dr Nicholas Tate

Chris Packham is the New St Francis of Assisi

15 May 2025
by Sallust

The Folly of Solar – a Dot on the Horizon Versus a Blight on the Land

27

Chinese ‘Kill Switches’ Found in US Solar Farms

27

Civil Servants Threaten to Strike Over Trans Ban in Women’s Lavatories

19

Spy Agency Report on the Alleged “Extremism” of AfD Turns Out to Be So Stupid That it Destroys all Momentum for Banning the Party

18

Chris Packham is the New St Francis of Assisi

39

Trump’s Lesson in Remedial Education

16 May 2025
by Dr James Allan

Spy Agency Report on the Alleged “Extremism” of AfD Turns Out to Be So Stupid That it Destroys all Momentum for Banning the Party

16 May 2025
by Eugyppius

The Folly of Solar – a Dot on the Horizon Versus a Blight on the Land

16 May 2025
by Ben Pile

Renaud Camus on the Destruction of Western Education

15 May 2025
by Dr Nicholas Tate

‘Why Can’t We Talk About This?’

15 May 2025
by Richard Eldred

POSTS BY DATE

May 2021
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
« Apr   Jun »

SOCIAL LINKS

Free Speech Union
  • Home
  • About us
  • Donate
  • Privacy Policy

Facebook

  • X

Instagram

RSS

Subscribe to our newsletter

© Skeptics Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Articles
  • About
  • Archive
    • ARCHIVE
    • NEWS ROUND-UPS
  • Podcasts
  • Newsletter
  • Premium
  • Donate
  • Log In

© Skeptics Ltd.

wpDiscuz
You are going to send email to

Move Comment